Clinical Trial

Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction

Study acronym: PADN-HFpEF
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
To assess the impact of PADN combined with guideline-directed medical therapy (GDMT) versus a sham procedure with GDMT on clinical outcomes in heart failure (HF) patients with preserved left ventricular ejection fraction (LVEF\>40%). Outcomes include cardiovascular death, HF-related rehospitalization, requirement for heart transplantation or need of valvular treatment or LVAD or pacemaker implantation, and worsening in outpatients (defined as requirement for intravenous therapy or diuretic intensification, including increasing the types or dose of diuretics).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-30.
Trial Details
NCT Number NCT07331220
Lead Sponsor Nanjing First Hospital, Nanjing Medical University
Collaborators: Nanjing Medical University
Conditions Heart Failure With Preserved Ejection Fraction
Enrollment 310 participants
Start Date 2026-12-30
Primary Completion 2028-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-27